Evonile Pharma (500672) Q2 24/25 earnings summary

Executive summary

• H1 revenue was 1,793.9 million and net profit was 461.5 million, compared with 1,693.6 million and 439.4 million YoY; Q2 revenue and profit were lower YoY.

• The board approved unaudited Q2 and H1 results on October 25, 2024; the auditor’s limited review found no matter causing concern over compliance or material misstatement.

Financial highlights

• Q2 revenue was 871.0 million versus 922.9 million YoY; H1 revenue was 1,793.9 million versus 1,693.6 million.

• Q2 profit before tax was 275.6 million versus 336.8 million; H1 profit before tax was 612.4 million versus 602.0 million YoY.

• Q2 net profit was 204.1 million versus 257.4 million; H1 net profit was 461.5 million versus 439.4 million YoY.

• Q2 EPS was 8.27 versus 10.42; H1 EPS was 18.69 versus 17.80 YoY.

Segment performance

• The business operates as a single Pharmaceuticals Business segment.